- Home
- MGRX vs CLDI Comparison
MGRX vs CLDI Comparison
Compare MGRX & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- CLDI
- Stock Information
- Founded
- MGRX 2021
- CLDI 2014
- Country
- MGRX United States
- CLDI United States
- Employees
- MGRX N/A
- CLDI N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGRX Technology
- CLDI Health Care
- Exchange
- MGRX Nasdaq
- CLDI Nasdaq
- Market Cap
- MGRX 18.6M
- CLDI 20.2M
- IPO Year
- MGRX 2023
- CLDI N/A
- Fundamental
- Price
- MGRX $1.73
- CLDI $1.76
- Analyst Decision
- MGRX
- CLDI
- Analyst Count
- MGRX 0
- CLDI 0
- Target Price
- MGRX N/A
- CLDI N/A
- AVG Volume (30 Days)
- MGRX 82.5K
- CLDI 1.1M
- Earning Date
- MGRX 08-14-2025
- CLDI 08-08-2025
- Dividend Yield
- MGRX N/A
- CLDI N/A
- EPS Growth
- MGRX N/A
- CLDI N/A
- EPS
- MGRX N/A
- CLDI N/A
- Revenue
- MGRX $516,030.00
- CLDI N/A
- Revenue This Year
- MGRX N/A
- CLDI N/A
- Revenue Next Year
- MGRX N/A
- CLDI N/A
- P/E Ratio
- MGRX N/A
- CLDI N/A
- Revenue Growth
- MGRX N/A
- CLDI N/A
- 52 Week Low
- MGRX $1.32
- CLDI $1.61
- 52 Week High
- MGRX $7.66
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- MGRX 53.47
- CLDI 29.56
- Support Level
- MGRX $1.42
- CLDI $1.61
- Resistance Level
- MGRX $1.76
- CLDI $6.06
- Average True Range (ATR)
- MGRX 0.14
- CLDI 0.77
- MACD
- MGRX -0.00
- CLDI -0.55
- Stochastic Oscillator
- MGRX 58.88
- CLDI 2.57
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.